Media coverage about Infinity Pharmaceuticals (NASDAQ:INFI) has trended somewhat positive on Sunday, Accern Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Infinity Pharmaceuticals earned a daily sentiment score of 0.13 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 47.1097424343871 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the news headlines that may have effected Accern’s scoring:
- Edited Transcript of INFI earnings conference call or presentation 7-Aug-18 8:30pm GMT (finance.yahoo.com)
- Roadblocks To A Successful Stocks: The Middleby Corporation (NASDAQ:MIDD), AMC Entertainment Holdings, Inc … (thestreetpoint.com)
- Infinity Pharmaceuticals, Inc. (INFI) Top Loser within Traders Spotlight (topdesertsafari.com)
- Infinity (INFI) Posts Narrower-Than-Expected Loss in Q2 (finance.yahoo.com)
- Is this stock Watchful?: Pluralsight, Inc. (PS), Infinity Pharmaceuticals, Inc. (INFI) (newsregistrar.com)
Infinity Pharmaceuticals traded up $0.01, hitting $2.11, during midday trading on Friday, Marketbeat reports. The company’s stock had a trading volume of 679,071 shares, compared to its average volume of 313,554. Infinity Pharmaceuticals has a 1-year low of $0.93 and a 1-year high of $3.75. The stock has a market capitalization of $119.10 million, a price-to-earnings ratio of -2.54 and a beta of 2.15.
Infinity Pharmaceuticals (NASDAQ:INFI) last issued its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.08. equities analysts forecast that Infinity Pharmaceuticals will post -0.54 EPS for the current year.
Several analysts have weighed in on the stock. ValuEngine upgraded shares of Infinity Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, August 3rd. Seaport Global Securities assumed coverage on shares of Infinity Pharmaceuticals in a research note on Thursday, May 31st. They issued a “buy” rating and a $4.00 price objective for the company. Finally, Zacks Investment Research cut shares of Infinity Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, May 16th.
In other news, insider Jeffery Kutok sold 14,313 shares of the business’s stock in a transaction that occurred on Friday, June 22nd. The shares were sold at an average price of $2.00, for a total value of $28,626.00. Following the completion of the transaction, the insider now directly owns 14,313 shares in the company, valued at approximately $28,626. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Bvf Partners L. P/Il bought 425,531 shares of the company’s stock in a transaction dated Thursday, June 21st. The stock was purchased at an average price of $1.65 per share, with a total value of $702,126.15. The disclosure for this purchase can be found here. 11.45% of the stock is owned by insiders.
About Infinity Pharmaceuticals
Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.
Featured Article: Average Daily Trade Volume – What You Need to Know
Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.